Abiraterone Inhibits 3β-Hydroxysteroid Dehydrogenase: A Rationale for Increasing Drug Exposure in Castration-Resistant Prostate Cancer

Purpose: Treatment with abiraterone (abi) acetate prolongs survival in castration-resistant prostate cancer (CRPC). Resistance to abi invariably occurs, probably due in part to upregulation of steroidogenic enzymes and/or other mechanisms that sustain dihydrotestosterone (DHT) synthesis, which raises the possibility of reversing resistance by concomitant inhibition of other required steroidogenic enzymes. On the basis of the 3β-hydroxyl, Δ5-structure, we hypothesized that abi also inhibits 3β-hydroxysteroid dehydrogenase/isomerase (3βHSD), which is absolutely required for DHT synthesis in CRPC, regardless of origins or routes of synthesis. Experimental Design: We tested the effects of abi on 3βHSD activity, androgen receptor localization, expression of androgen receptor–responsive genes, and CRPC growth in vivo. Results: Abi inhibits recombinant 3βHSD activity in vitro and endogenous 3βHSD activity in LNCaP and LAPC4 cells, including conversion of [3H]-dehydroepiandrosterone (DHEA) to Δ4-androstenedione, androgen receptor nuclear translocation, expression of androgen receptor–responsive genes, and xenograft growth in orchiectomized mice supplemented with DHEA. Abi also blocks conversion of Δ5-androstenediol to testosterone by 3βHSD. Abi inhibits 3βHSD1 and 3βHSD2 enzymatic activity in vitro; blocks conversion from DHEA to androstenedione and DHT with an IC50 value of less than 1 μmol/L in CRPC cell lines; inhibits androgen receptor nuclear translocation; expression of TMPRSS2, prostate-specific antigen, and FKBP5; and decreases CRPC xenograft growth in DHEA-supplemented mice. Conclusions: We conclude that abi inhibits 3βHSD-mediated conversion of DHEA to active androgens in CRPC. This second mode of action might be exploited to reverse resistance to CYP17A1 inhibition at the standard abi dose by dose-escalation or simply by administration with food to increase drug exposure. Clin Cancer Res; 18(13); 3571–9. ©2012 AACR.

[1]  M. Dowsett,et al.  Clinical and biochemical consequences of CYP17A1 inhibition with abiraterone given with and without exogenous glucocorticoids in castrate men with advanced prostate cancer. , 2012, The Journal of clinical endocrinology and metabolism.

[2]  N. Sharifi.  The 5α-Androstanedione Pathway to Dihydrotestosterone in Castration-Resistant Prostate Cancer , 2012, Journal of Investigative Medicine.

[3]  Stanislav Ziaran.  Androgen Deprivation Therapy for Prostate Cancer , 2011 .

[4]  P. Nelson,et al.  Intratumoral de novo steroid synthesis activates androgen receptor in castration-resistant prostate cancer and is upregulated by treatment with CYP17A1 inhibitors. , 2011, Cancer research.

[5]  D. Tindall,et al.  Androgen receptor rediscovered: the new biology and targeting the androgen receptor therapeutically. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[6]  P. Nelson,et al.  Resistance to CYP17A1 Inhibition with Abiraterone in Castration-Resistant Prostate Cancer: Induction of Steroidogenesis and Androgen Receptor Splice Variants , 2011, Clinical Cancer Research.

[7]  Rui Li,et al.  Dihydrotestosterone synthesis bypasses testosterone to drive castration-resistant prostate cancer , 2011, Proceedings of the National Academy of Sciences.

[8]  Arturo Molina,et al.  Abiraterone and increased survival in metastatic prostate cancer. , 2011, The New England journal of medicine.

[9]  K. Knudsen,et al.  Outsmarting androgen receptor: creative approaches for targeting aberrant androgen signaling in advanced prostate cancer , 2011, Expert review of endocrinology & metabolism.

[10]  W. Miller,et al.  The molecular biology, biochemistry, and physiology of human steroidogenesis and its disorders. , 2011, Endocrine reviews.

[11]  R. Auchus,et al.  3beta-hydroxysteroid dehydrogenase is a possible pharmacological target in the treatment of castration-resistant prostate cancer. , 2010, Endocrinology.

[12]  N. Sharifi.  New agents and strategies for the hormonal treatment of castration-resistant prostate cancer , 2010, Expert opinion on investigational drugs.

[13]  P. Kantoff,et al.  Phase I clinical trial of the CYP17 inhibitor abiraterone acetate demonstrating clinical activity in patients with castration-resistant prostate cancer who received prior ketoconazole therapy. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[14]  S. Balk,et al.  Reactivation of androgen receptor-regulated TMPRSS2:ERG gene expression in castration-resistant prostate cancer. , 2009, Cancer research.

[15]  M. Dowsett,et al.  Phase I clinical trial of a selective inhibitor of CYP17, abiraterone acetate, confirms that castration-resistant prostate cancer commonly remains hormone driven. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[16]  P. Nelson,et al.  Maintenance of intratumoral androgens in metastatic prostate cancer: a mechanism for castration-resistant tumor growth. , 2008, Cancer research.

[17]  H. Scher,et al.  Biology of progressive, castration-resistant prostate cancer: directed therapies targeting the androgen-receptor signaling axis. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[18]  K. Tomer,et al.  Testosterone and Dihydrotestosterone Tissue Levels in Recurrent Prostate Cancer , 2005, Clinical Cancer Research.

[19]  Jacques Simard,et al.  Molecular Biology of the 3-Hydroxysteroid Dehydrogenase/5-4 Isomerase Gene Family , 2005 .

[20]  H. Fujita,et al.  The Adrenal Androgen Androstenediol Is Present in Prostate Cancer Tissue after Androgen Deprivation Therapy and Activates Mutated Androgen Receptor , 2004, Cancer Research.

[21]  W. Cai,et al.  A Practical Synthesis of Pyridylboranes via Magnesium—Halogen Exchange. , 2002 .

[22]  W L Miller,et al.  Medroxyprogesterone acetate and dexamethasone are competitive inhibitors of different human steroidogenic enzymes. , 1999, The Journal of clinical endocrinology and metabolism.

[23]  M. Rowlands,et al.  Novel Steroidal Inhibitors of Human Cytochrome P45017α (17α -Hydroxylase-C17,20-lyase): Potential Agents for the Treatment of Prostatic Cancer. , 1995 .

[24]  M. Rowlands,et al.  Novel steroidal inhibitors of human cytochrome P45017 alpha (17 alpha-hydroxylase-C17,20-lyase): potential agents for the treatment of prostatic cancer. , 1995, Journal of medicinal chemistry.

[25]  B. Haynes,et al.  Pharmacology of novel steroidal inhibitors of cytochrome P45017α (17α-hydroxylase/C17–20 lyase) , 1994, The Journal of Steroid Biochemistry and Molecular Biology.

[26]  J. Mason,et al.  Human 3 beta-hydroxysteroid dehydrogenase/delta 5----4isomerase from placenta: expression in nonsteroidogenic cells of a protein that catalyzes the dehydrogenation/isomerization of C21 and C19 steroids. , 1990, Endocrinology.

[27]  Albert L. Jerry,et al.  DHT Concentrations in Human Prostate Cancer Tissue , 1978 .

[28]  Á. Száz.  Minimal structures , generalized topologies , and ascending systems should not be studied without generalized uniformities , 2007 .

[29]  F. Schröder,et al.  Adrenal glands of mouse and rat do not synthesize androgens. , 1992, Life sciences.

[30]  J. Geller,et al.  DHT concentrations in human prostate cancer tissue. , 1978, The Journal of clinical endocrinology and metabolism.